Seaport Therapeutics, Inc. Temporary Equity, Liquidation Preference
Seaport Therapeutics, Inc. (SPTX) had Temporary Equity, Liquidation Preference of $330.10 million as of 2026-03-31, per its 10-Q filed 2026-06-08.
Financial Statements › Balance Sheet › Equity › Temporary Equity › Temporary Equity, Other Disclosure
us-gaap:TemporaryEquityLiquidationPreference · last filed 2026-08-03
- 2026-03-31: Temporary Equity, Liquidation Preference $330.10M.
- 2025-12-31: Temporary Equity, Liquidation Preference $330.10M.
| Period end | Temporary Equity, Liquidation Preference |
|---|---|
| 2026-03-31 | $330.10M 10-Q · filed 2026-06-08 |
| 2025-12-31 | $330.10M 10-Q · filed 2026-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |